Comparative Pharmacology
Head-to-head clinical analysis: CYCLOBENZAPRINE HYDROCHLORIDE versus PARSIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOBENZAPRINE HYDROCHLORIDE versus PARSIDOL.
CYCLOBENZAPRINE HYDROCHLORIDE vs PARSIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclobenzaprine is a centrally acting muscle relaxant that reduces tonic somatic motor activity at the supraspinal level, primarily at the brainstem reticular formation and descending pathways. It is structurally related to tricyclic antidepressants and inhibits reuptake of norepinephrine and serotonin, but the direct relationship to its muscle relaxant effects is not fully established.
Parsidol (ethopropazine) is a phenothiazine derivative that acts as an anticholinergic agent. It inhibits the action of acetylcholine at muscarinic receptors, thereby reducing cholinergic activity in the basal ganglia and restoring the balance between dopaminergic and cholinergic neurotransmission. It also has some dopamine reuptake inhibition and antihistaminic properties.
Adults: 5 mg orally three times daily; may increase to 10 mg three times daily based on response. Maximum 30 mg per day.
Oral: 2.5-5 mg twice daily, gradually increased to 5-10 mg three times daily; maximum 60 mg/day.
None Documented
None Documented
Terminal half-life: 18–24 hours (range 8–37 hours). Clinical context: requires multiple doses to achieve steady state (5–6 days); active metabolite norcyclobenzaprine has half-life ~30 hours.
Terminal elimination half-life: 12-24 hours (prolonged in elderly and renal impairment, requiring dose adjustment).
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40% primarily as metabolites; Biliary: minimal.
Renal: 60-70% as unchanged drug; biliary/fecal: 15-20% as metabolites; minor respiratory elimination.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant